Monument publie les résultats financiers de son deuxième trimestre 2025
VANCOUVER, Province de Colombie-Britannique, 01 mars 2025 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V : MMY et FSE : D7Q1), ci-après « Monument » ou la « Société », publie…
Verb to Acquire AI Social Selling Startup LyveCom
LOS ALAMITOS, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Verb Technology Company, Inc. (Nasdaq: VERB) ("VERB" or the "Company"), the technology company behind MARKET.live, a leading livestream social shopping platform,…
Form 8.3 – Warehouse REIT Plc
8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full…
Monument veröffentlicht Finanzergebnisse für das zweite Quartal 2025
VANCOUVER, British Columbia, March 01, 2025 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY und FSE: D7Q1) „Monument“ oder das „Unternehmen“ gab heute seine Finanzergebnisse für die drei Monate („Q2…
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating…
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN) (“ACELYRIN”) today reaffirmed their commitment to merge…
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq:…
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting…
49-Year Business Graphics 3 Sold to New Minuteman Press Franchise Owner Tyler Griffith in Coldwater, MI
COLDWATER, Mich., March 04, 2025 (GLOBE NEWSWIRE) -- Graphics 3, a second-generation printing business owned by Iveson family for 49 years, has been sold by retiring owner Mike Iveson to…
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU -- 82% of CSU patients reported that symptoms no longer had an impact…